Difference between revisions of "Citalopram-moclobemide"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
* '''Day 15:''' start administration of moclobemide in normal dosage of 300 mg/day.  
 
* '''Day 15:''' start administration of moclobemide in normal dosage of 300 mg/day.  
 
| caveat =  
 
| caveat =  
* Occurrence of serotonin syndrome is reported when a wash-out period (of 2 weeks) is not considered.
+
{{caveSS}}
 
| info =  
 
| info =  
 
* The same applies to [[escitalopram]].}}
 
* The same applies to [[escitalopram]].}}

Revision as of 15:59, 6 August 2009

Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from citalopram to moclobemide.[1] [2]

Nietinrijdenbord.png Stop citalopram
  • Day 0: gradually reduce dosage of citalopram/escitalopram to a maximum of 20 mg/ day resp. 10 mg/day, when this dosage is respectively > 20 mg/day and > 10 mg/day.
  • Day 1: reduce dosage of citalopram/escitalopram to a maximum of 10 mg/ day resp. 5 mg/day.
  • Day 8: stop administration of citalopram/escitalopram.
Eenrichtingbord.png Start moclobemide
  • Day 8-14: a wash-out period of 2 weeks is necessary.
  • Day 15: start administration of moclobemide in normal dosage of 300 mg/day.
Letopbord.png Cave
Infobord.png More information
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.